Get the Stockscreener App
51.33
1.08%
-0.56
After Hours:
51.33
Monopar Therapeutics Inc Stock (MNPR) Latest News
Brookline Capital Management Forecasts MNPR Q1 Earnings - Defense World
Q1 EPS Forecast for Monopar Therapeutics Raised by Analyst - MarketBeat
Monopar's Incredible Journey From $5 To $50 In Less Than 5 Months - Nasdaq
Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 - MSN
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
(MNPR) Trading Report - Stock Traders Daily
What's Going On With Cancer-Focused Monopar Therapeutics Stock Today? - MSN
What is HC Wainwright’s Forecast for MNPR FY2026 Earnings? - Defense World
Monopar Therapeutics Stock Hits 52-Week High at $38.91 - MSN
Analysts Set Expectations for MNPR FY2029 Earnings - MarketBeat
What is HC Wainwright's Forecast for MNPR FY2026 Earnings? - MarketBeat
Monopar Therapeutics Stock Hits 52-Week High at $38.91 By Investing.com - Investing.com South Africa
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics - PR Newswire
Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright - Yahoo Finance
Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $40.00 - MarketBeat
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy - MSN
Up 1,000% in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket - MSN
Piper Sandler Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR) - Defense World
Piper Sandler Initiates Coverage of Monopar Therapeutics (MNPR) with Overweight Recommendation - MSN
(MNPR) Trading Advice - Stock Traders Daily
Piper Sandler Initiates Coverage on Monopar Therapeutics (NASDAQ:MNPR) - MarketBeat
Brookline Capital Management Comments on MNPR Q1 Earnings - Defense World
Brookline Capital Management Predicts MNPR Q1 Earnings - MarketBeat
How To Know If Monopar Therapeutics Inc (NASDAQ:MNPR) Is Expensive At $24.46. - Marketing Sentinel
JANUS HENDERSON GROUP PLC Acquires Additional Shares in Monopar Therapeutics Inc - GuruFocus.com
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN - MSN
How the (MNPR) price action is used to our Advantage - Stock Traders Daily
These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year — Here’s What Analysts Expect in 2025 - Yahoo Finance
Monopar Therapeutics Inc. Enters Into Underwritten Registered Offering and Concurrent Private PlacementOn December 20, 2024, Monopar Therapeutics Inc. (NASDAQ: MNPR) finalized an Underwriting Agreement with Piper Sandler & Co. to conduct an Und - Defense World
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024 - Zacks Investment Research
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways (MNPR) - Seeking Alpha
(MNPR) Technical Data - Stock Traders Daily
Monopar Therapeutics announces pricing of $40M public offering of common stock - MSN
Best-Performing Small-Cap Stocks of 2024 - Investing.com
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants - The Manila Times
Monopar Therapeutics sets stock and warrant offering prices - Investing.com
Here's What Could Help Monopar Therapeutics (MNPR) Maintain Its Recent Price Strength - MSN
When the Price of (MNPR) Talks, People Listen - Stock Traders Daily
Monopar Therapeutics Achieves Milestone in Cancer Treatment - TipRanks
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu - EIN News
Monopar's Novel Radiopharmaceutical MNPR-101-Lu Achieves First-Ever Patient Dosing Milestone - StockTitan
Oral Mucositis Market expected to rise | Companies- Galera Therapeutics, Soligenix, Izun Pharma, MitoImmune Therapeutics, Tosk, Cellix Bio, Enzychem Lifesciences, Monopar Therapeutics - The Globe and Mail
What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing' - MSN
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
3 Momentum Stocks Soaring Into 2025 and Beyond - sharewise
Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus - Seeking Alpha
(MNPR) Proactive Strategies - Stock Traders Daily
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):